Olmetec and Abdominal pain - a phase IV clinical study of FDA data

Summary:

Abdominal pain is reported as a side effect among people who take Olmetec (olmesartan medoxomil), especially for people who are male, 60+ old, have been taking the drug for 2 - 5 years also take Norvasc, and have Crohn's disease.

The phase IV clinical study analyzes which people have Abdominal pain when taking Olmetec. It is created by eHealthMe based on reports of 7,816 people who have side effects when taking Olmetec from the FDA, and is updated regularly.

What is Olmetec?

Olmetec has active ingredients of olmesartan medoxomil. It is often used in high blood pressure. eHealthMe is studying from 7,904 Olmetec users. Check the latest studies of Olmetec.

What is Abdominal pain?

Abdominal pain is found to be associated with 3,219 drugs and 5,754 conditions by eHealthMe. Check the latest studies of Abdominal pain.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 31, 2026

7,816 people reported to have side effects when taking Olmetec.
Among them, 138 people (1.77%) have Abdominal pain.

Among these 138 people:

* Approximation only. Some reports may have incomplete information.

Do you take Olmetec and have Abdominal pain?

- Check whether Abdominal pain is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Olmetec:

Olmetec (7,904 reports)

Abdominal pain treatments and more:

Abdominal pain (286,410 reports)

How severe was Abdominal pain and when was it recovered:

Abdominal pain in Olmetec

Expand to all the drugs that have ingredients of olmesartan medoxomil:

Abdominal pain and drugs with ingredients of olmesartan medoxomil (1,254 reports)

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Olmetec:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Abdominal pain:

Abdominal pain (3,219 drugs)

Browse all the conditions that are associated with Abdominal pain:

Abdominal pain (5,754 conditions)

Related publications that referenced our studies

Bhuvan KC, ALrasheedy AA, Ibrahim MI, "A case report from Nepalese community pharmacy on levofloxacin induced severe abdominal pain", Saudi Pharmaceutical Journal, 2013 Jul .
Bhuvan KC, ALrasheedy AA, Ibrahim MI, "A case report from Nepalese community pharmacy on levofloxacin induced severe abdominal pain", Saudi Pharmaceutical Journal, 2013 Jul .

How the study uses the data?

The study uses data from the FDA. It is based on olmesartan medoxomil (the active ingredients of Olmetec) and Olmetec (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.